Also, in patients with advanced NSCLC treated with anti-PD1, a lower percentage of the terminal exhausted peripheral Eomes+ PD1+ CD8+ subgroup showed an improved outcome [97]. Here, PDCD1 is linked to non-small cell lung carcinoma.